GB2106111B
(en)
*
|
1981-09-17 |
1985-11-06 |
Takeda Chemical Industries Ltd |
Macbecin derivatives and their production
|
US4578391A
(en)
*
|
1982-01-20 |
1986-03-25 |
Yamanouchi Pharmaceutical Co., Ltd. |
Oily compositions of antitumor drugs
|
JPS59102398A
(ja)
*
|
1982-12-03 |
1984-06-13 |
Takeda Chem Ind Ltd |
新規抗生物質およびその製造法
|
WO1994008578A2
(en)
*
|
1992-10-14 |
1994-04-28 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
|
US5387584A
(en)
*
|
1993-04-07 |
1995-02-07 |
Pfizer Inc. |
Bicyclic ansamycins
|
EP0706516A1
(en)
*
|
1993-06-29 |
1996-04-17 |
Pfizer Inc. |
Ansamycin derivatives as antioncogene and anticancer agents
|
US5932566A
(en)
*
|
1994-06-16 |
1999-08-03 |
Pfizer Inc. |
Ansamycin derivatives as antioncogene and anticancer agents
|
JPH11504924A
(ja)
*
|
1995-05-02 |
1999-05-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ベンゾキノン類アンサマイシンによる熱耐性の誘導
|
ATE460423T1
(de)
|
1997-05-14 |
2010-03-15 |
Sloan Kettering Inst Cancer |
Verfahren und zubereitungen zur zerstörung bestimmter proteine
|
US6852496B1
(en)
*
|
1997-08-12 |
2005-02-08 |
Oregon Health And Science University |
Methods of screening for agents that promote nerve cell growth
|
US6747055B1
(en)
*
|
1998-07-17 |
2004-06-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Water-soluble drugs and methods for their production
|
EP1098666B1
(en)
|
1998-07-17 |
2013-01-16 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Water-soluble drugs and methods for their production
|
ID29393A
(id)
*
|
1998-12-07 |
2001-08-30 |
Ecosmart Technologies Inc |
Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
|
US6174875B1
(en)
*
|
1999-04-01 |
2001-01-16 |
University Of Pittsburgh |
Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
|
US7238682B1
(en)
|
1999-04-09 |
2007-07-03 |
Sloan-Kettering Institute For Cancer Research |
Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases
|
JP2002541255A
(ja)
|
1999-04-09 |
2002-12-03 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
Her族チロシンキナーゼの分解および/または阻害方法および組成物
|
US6979574B1
(en)
*
|
1999-08-06 |
2005-12-27 |
Institut Fuer Diagnostik Forshung Gmbh |
Process for detecting binding reactions with use of the measurement of the relaxation of the double refraction of magnetic particles
|
US6887853B2
(en)
*
|
2000-06-29 |
2005-05-03 |
The Trustees Of Boston University |
Use of geldanamycin and related compounds for treatment of fibrogenic disorders
|
EP1322307B1
(en)
|
2000-07-28 |
2011-09-28 |
Sloan-Kettering Institute For Cancer Research |
Methods for treating cell proliferative disorders and viral infections
|
CN1473055A
(zh)
|
2000-11-02 |
2004-02-04 |
˹¡-�����ְ�֢�о��� |
通过使用hsp90抑制剂提高细胞毒剂效力的方法
|
US20060079493A1
(en)
*
|
2001-03-01 |
2006-04-13 |
Lawrence Fritz |
Methods for treating genetically- defined proliferative disorders with hsp90 inhibitors
|
WO2002079167A1
(en)
*
|
2001-03-30 |
2002-10-10 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Geldanamycin derivative and method of treating cancer using same
|
US7825094B2
(en)
*
|
2001-05-23 |
2010-11-02 |
Sloan-Kettering Institute For Cancer Research |
Method of treatment for cancers associated with elevated HER 2 levels
|
US20090197852A9
(en)
*
|
2001-08-06 |
2009-08-06 |
Johnson Robert G Jr |
Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
|
US6872715B2
(en)
|
2001-08-06 |
2005-03-29 |
Kosan Biosciences, Inc. |
Benzoquinone ansamycins
|
WO2003013430A2
(en)
*
|
2001-08-06 |
2003-02-20 |
Kosan Biosciences, Inc. |
Benzoquinone ansamycins
|
DE60225307T2
(de)
*
|
2001-09-24 |
2009-03-19 |
Conforma Therapeutics Corp., San Diego |
Verfahren zur herstellung von 17-allyl-amino-geldanamycin (17-aag) und anderer ansamycine
|
EP1923061A1
(en)
|
2001-09-24 |
2008-05-21 |
Conforma Therapeutic Corporation |
Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
|
ATE433961T1
(de)
*
|
2002-02-08 |
2009-07-15 |
Conforma Therapeutics Corp |
Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
|
EP1492522A4
(en)
*
|
2002-04-10 |
2009-01-14 |
Conforma Therapeutics Corp |
ANSAMYCIN FORMULATIONS AND METHODS OF MAKING AND USING THE SAME
|
US20060148776A1
(en)
*
|
2003-03-13 |
2006-07-06 |
Conforma Therapeutics Corporation |
Drug formulations having long and medium chain triglycerides
|
US7691838B2
(en)
*
|
2003-05-30 |
2010-04-06 |
Kosan Biosciences Incorporated |
Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
|
US20050054589A1
(en)
*
|
2003-05-30 |
2005-03-10 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
|
US20050020556A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
|
US20050020534A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
|
US20050020557A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
|
US20050054625A1
(en)
*
|
2003-05-30 |
2005-03-10 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
|
US20050026893A1
(en)
*
|
2003-05-30 |
2005-02-03 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
|
US7241754B2
(en)
*
|
2003-06-13 |
2007-07-10 |
Kosan Biosciences, Inc. |
2-Desmethyl ansamycin compounds
|
US6887993B1
(en)
|
2003-11-12 |
2005-05-03 |
Kosan Biosciences, Inc. |
11-O-methylgeldanamycin compounds
|
US6870049B1
(en)
|
2003-11-12 |
2005-03-22 |
Kosan Biosciences, Inc. |
11-O-methylgeldanamycin compounds
|
US6855705B1
(en)
|
2003-11-12 |
2005-02-15 |
Kosan Biosciences, Inc. |
11-O-methylgeldanamycin compounds
|
US6875863B1
(en)
|
2003-11-12 |
2005-04-05 |
Kosan Biosciences, Inc. |
11-O-methylgeldanamycin compounds
|
US20060019941A1
(en)
*
|
2003-12-23 |
2006-01-26 |
Infinity Pharmaceuticals, Inc. |
Analogs of benzoquinone-containing ansamycins and methods of use thereof
|
CN102643233B
(zh)
|
2003-12-23 |
2015-11-25 |
无限发现公司 |
用于治疗癌症的包含苯醌的安沙霉素类似物
|
WO2005072766A2
(en)
*
|
2004-01-27 |
2005-08-11 |
Boys Town National Research Hospital |
Peptides that bind to hsp90 proteins
|
AU2005222607B2
(en)
|
2004-03-15 |
2010-11-25 |
Sunesis Pharmaceuticals, Inc. |
SNS-595 and methods of using the same
|
US20050267087A1
(en)
*
|
2004-04-28 |
2005-12-01 |
Vassiliki Poulaki |
Inflammatory eye disease
|
US20050256097A1
(en)
*
|
2004-05-11 |
2005-11-17 |
Kosan Biosciences, Inc. |
Pharmaceutical solution formulations containing 17-AAG
|
US7259156B2
(en)
|
2004-05-20 |
2007-08-21 |
Kosan Biosciences Incorporated |
Geldanamycin compounds and method of use
|
US20080171687A1
(en)
*
|
2004-09-16 |
2008-07-17 |
Abraxis Bioscience, Inc. |
Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
|
US20060067953A1
(en)
*
|
2004-09-29 |
2006-03-30 |
Conforma Therapeutics Corporation |
Oral pharmaceutical formulations and methods for producing and using same
|
EP2896412A1
(en)
*
|
2005-02-18 |
2015-07-22 |
Abraxis BioScience, LLC |
Drugs with improved hydrophobicity for incorporation in medical devices
|
JP2008534609A
(ja)
|
2005-03-30 |
2008-08-28 |
コンフォーマ・セラピューティクス・コーポレイション |
Hsp90阻害剤としてのアルキニルピロロピリミジンおよび関連類似体
|
BRPI0608661A2
(pt)
*
|
2005-04-07 |
2010-01-19 |
Conforma Therapeutics Corp |
formulaÇço farmacÊutica, uso de formulaÇço farmacÊutica, e, mÉtodo de preparaÇço de uma formulaÇço farmacÊutica
|
CA2603987A1
(en)
|
2005-04-12 |
2006-10-19 |
Wisconsin Alumni Research Foundation |
Micelle composition of polymer and passenger drug
|
RU2007144195A
(ru)
*
|
2005-04-29 |
2009-06-10 |
Козан Байосайенсиз Инкорпорейтед (Us) |
Способ лечения множественной миеломы с использованием 17-aag или 17-ag или пролекарства любого из них
|
MX2007013499A
(es)
*
|
2005-04-29 |
2008-01-24 |
Kosan Biosciences Inc |
Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag en combinacion con un inhibidor de proteasoma.
|
US20080032719A1
(en)
*
|
2005-10-01 |
2008-02-07 |
Outland Research, Llc |
Centralized establishment-based tracking and messaging service
|
WO2007002093A2
(en)
*
|
2005-06-21 |
2007-01-04 |
Infinity Discovery, Inc. |
Ansamycin formulations and methods of use thereof
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
WO2007035963A2
(en)
*
|
2005-09-23 |
2007-03-29 |
Conforma Therapeutics Corporation |
Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
|
US7648976B2
(en)
*
|
2005-11-23 |
2010-01-19 |
Bristol-Myers Squibb Company |
17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
|
US20090042847A1
(en)
*
|
2005-11-23 |
2009-02-12 |
Kosan Biosciences Incorporated |
17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
|
EP1954265A2
(en)
*
|
2005-12-01 |
2008-08-13 |
Conforma Therapeutics Corporation |
Compositions containing ansamycin
|
US20070167422A1
(en)
*
|
2006-01-18 |
2007-07-19 |
Yu Kwok S |
Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
|
WO2007097839A2
(en)
*
|
2006-02-16 |
2007-08-30 |
Massachusetts Eye And Ear Infirmary |
Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
|
US8124773B2
(en)
|
2006-06-12 |
2012-02-28 |
Sunesis Pharmaceuticals, Inc. |
1,8-naphthyridine compounds for the treatment of cancer
|
HUE026693T2
(hu)
*
|
2006-08-02 |
2016-07-28 |
Sunesis Pharmaceuticals Inc |
(+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil) -1,8-naftiridin-3-karbonsav és cytarabin (Ara-C) kombinált alkalmazása leukémia kezelésére
|
PE20081506A1
(es)
*
|
2006-12-12 |
2008-12-09 |
Infinity Discovery Inc |
Formulaciones de ansamicina
|
WO2008094438A1
(en)
|
2007-01-26 |
2008-08-07 |
Kosan Biosciences Incorporated |
Macrolactams by engineered biosynthesis
|
WO2008118601A2
(en)
*
|
2007-02-27 |
2008-10-02 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Radiolabeled affibody molecules
|
AU2008240153B2
(en)
*
|
2007-04-12 |
2013-01-31 |
Joyant Pharmaceuticals, Inc. |
SMAC mimetic dimers and trimers useful as anti-cancer agents
|
US20080255080A1
(en)
*
|
2007-04-12 |
2008-10-16 |
Wright James L |
Hydroquinone Ansamycin Formulations
|
JP2010533180A
(ja)
*
|
2007-07-09 |
2010-10-21 |
グレン エス. クウォン, |
治療剤
|
WO2009026548A1
(en)
*
|
2007-08-23 |
2009-02-26 |
The Regents Of The University Of Colorado |
Hsp90 inhibitors with modified toxicity
|
JP2011501731A
(ja)
*
|
2007-09-10 |
2011-01-13 |
ユニバーシティ オブ マサチューセッツ |
ミトコンドリア標的化抗腫瘍剤
|
CN101909613A
(zh)
*
|
2007-10-22 |
2010-12-08 |
逊尼希思制药公司 |
在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法
|
US7960420B2
(en)
*
|
2007-12-21 |
2011-06-14 |
Joyant Pharmaceuticals, Inc |
Diazonamide analogs with improved solubility
|
CN101220068B
(zh)
*
|
2008-01-18 |
2012-06-13 |
中国医学科学院医药生物技术研究所 |
一组格尔德霉素衍生物及其制备方法
|
US20090258869A1
(en)
*
|
2008-02-08 |
2009-10-15 |
The Regents Of The University Of California |
Methods and compounds for treatment or prevention of substance-related disorders
|
AU2009243056B2
(en)
*
|
2008-04-29 |
2015-05-14 |
Joyant Pharmaceuticals, Inc. |
Indoline anti-cancer agents
|
US8153619B2
(en)
*
|
2008-05-22 |
2012-04-10 |
Joyant Pharmaceuticals, Inc. |
Diazonamide analogs
|
EP2348845A4
(en)
*
|
2008-10-15 |
2013-01-23 |
Infinity Pharmaceuticals Inc |
ANSAMYCIN HYDROQUINONE COMPOSITIONS
|
DE102008060549A1
(de)
|
2008-12-04 |
2010-06-10 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
|
US8236329B2
(en)
*
|
2009-09-25 |
2012-08-07 |
Wisconsin Alumni Research Foundation |
Micelle encapsulation of therapeutic agents
|
EP2471918A4
(en)
|
2009-09-29 |
2013-06-05 |
Takeda Pharmaceutical |
SCREENING PROCESS
|
EP2784076A1
(en)
|
2009-10-28 |
2014-10-01 |
Joyant Pharmaceuticals, Inc. |
Dimeric SMAC mimetics
|
CN102603635B
(zh)
*
|
2011-01-21 |
2016-08-03 |
杭州华东医药集团生物工程研究所有限公司 |
格尔德霉素衍生物及其制备方法和用途
|
RU2608308C2
(ru)
|
2011-04-22 |
2017-01-17 |
Джоянт Фармасьютикалс, Инк. |
Аналоги диазонамида
|
WO2012151544A1
(en)
|
2011-05-05 |
2012-11-08 |
Wisconsin Alumni Research Foundation |
Micelles for the solubilization of gossypol
|
CA2851383A1
(en)
|
2011-10-14 |
2013-04-18 |
Xizhong Huang |
2 - carboxamide cycloamino urea derivatives in combination with hsp90 inhibitors for the treatment of proliferative diseases
|
WO2013074695A1
(en)
|
2011-11-14 |
2013-05-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Hsp90 inhibitors with modified toxicity
|
AU2013208720A1
(en)
|
2012-01-09 |
2014-07-24 |
Arrowhead Research Corporation |
RNAi agents to treat Beta-Catenin related diseases
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
EP3795694A3
(en)
|
2012-10-02 |
2021-06-23 |
The General Hospital Corporation d/b/a Massachusetts General Hospital |
Methods relating to dna-sensing pathway related conditions
|
RU2015121424A
(ru)
|
2012-11-07 |
2016-12-27 |
Новартис Аг |
Комбинированная терапия
|
ME03061B
(me)
|
2013-02-19 |
2019-01-20 |
Novartis Ag |
Derivati benzotiofena i njihove kompozicije kao selektivni degraderi estrogenskog receptora
|
CN103360312B
(zh)
*
|
2013-07-22 |
2015-06-03 |
山东大学 |
一组格尔德霉素衍生物及其应用
|
US9993460B2
(en)
|
2013-07-26 |
2018-06-12 |
Race Oncology Ltd. |
Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
US10093646B2
(en)
|
2014-01-17 |
2018-10-09 |
Novartis Ag |
1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
|
WO2015107494A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
WO2016151499A1
(en)
|
2015-03-25 |
2016-09-29 |
Novartis Ag |
Formylated n-heterocyclic derivatives as fgfr4 inhibitors
|
JP6898862B2
(ja)
|
2015-06-12 |
2021-07-07 |
ウイスコンシン アラムニ リサーチ ファンデーション |
放射線増感剤として作用する多剤複合薬
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
CN112625028A
(zh)
|
2015-06-19 |
2021-04-09 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
US10308660B2
(en)
|
2015-06-19 |
2019-06-04 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
DK3452465T3
(da)
|
2016-05-04 |
2021-02-08 |
Genoscience Pharma |
Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
|
ES2810852T3
(es)
|
2016-06-14 |
2021-03-09 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de shp2
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
JP7447002B2
(ja)
|
2017-09-11 |
2024-03-11 |
クルーゾン・ファーマシューティカルズ・インコーポレイテッド |
SHP2のオクタヒドロシクロペンタ[c]ピロールのアロステリック阻害剤
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
EP3826686A1
(en)
|
2018-07-25 |
2021-06-02 |
Advanced Accelerator Applications S.A. |
Stable, concentrated radionuclide complex solutions
|
US20200115389A1
(en)
|
2018-09-18 |
2020-04-16 |
Nikang Therapeutics, Inc. |
Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
|
CN113382986A
(zh)
|
2018-09-25 |
2021-09-10 |
黑钻治疗公司 |
酪氨酸激酶抑制剂组合物、其制备方法和使用方法
|
CN113164776A
(zh)
|
2018-09-25 |
2021-07-23 |
黑钻治疗公司 |
酪氨酸激酶抑制剂组合物、其制备方法和使用方法
|
JP7358484B2
(ja)
|
2018-09-25 |
2023-10-10 |
アドヴァンスド・アクセラレーター・アプリケーションズ・(イタリー)・エッセエッレエッレ |
併用療法
|
EP3856345A1
(en)
|
2018-09-29 |
2021-08-04 |
Novartis AG |
Process of manufacture of a compound for inhibiting the activity of shp2
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
MX2021009763A
(es)
|
2019-02-15 |
2021-09-08 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
|
MX2022001952A
(es)
|
2019-08-15 |
2022-06-02 |
Black Diamond Therapeutics Inc |
Compuestos de alquinil quinazolina.
|
JP2023507190A
(ja)
|
2019-12-20 |
2023-02-21 |
ノバルティス アーゲー |
増殖性疾患を治療するための抗TGFβ抗体及びチェックポイント阻害薬の使用
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
WO2022029573A1
(en)
|
2020-08-03 |
2022-02-10 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
WO2022140472A1
(en)
|
2020-12-22 |
2022-06-30 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
WO2022152821A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
WO2022219412A1
(en)
|
2021-04-14 |
2022-10-20 |
Monte Rosa Therapeutics Ag |
Isoindolinone amide compounds useful to treat diseases associated with gspt1
|
EP4323350A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone compounds
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
EP4370522A1
(en)
|
2021-07-14 |
2024-05-22 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
TW202346292A
(zh)
|
2022-03-28 |
2023-12-01 |
美商尼坎醫療公司 |
作為週期蛋白依賴性激酶2抑制劑的磺醯胺基衍生物
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023240024A1
(en)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2024102849A1
(en)
|
2022-11-11 |
2024-05-16 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|